Shield Therapeutics (LSE:STX) FCF Margin % : -497.00% (As of Jun. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Shield Therapeutics's Free Cash Flow for the six months ended in Jun. 2023 was £-21.54 Mil. Shield Therapeutics's Revenue for the six months ended in Jun. 2023 was £4.33 Mil. Therefore, Shield Therapeutics's FCF Margin % for the quarter that ended in Jun. 2023 was -497.00%.

As of today, Shield Therapeutics's current FCF Yield % is -204.82%.

The historical rank and industry rank for Shield Therapeutics's FCF Margin % or its related term are showing as below:

LSE:STX' s FCF Margin % Range Over the Past 10 Years
Min: -4418.09 Med: -758 Max: -13.7
Current: -401.31

During the past 9 years, the highest FCF Margin % of Shield Therapeutics was -13.70%. The lowest was -4418.09%. And the median was -758.00%.

LSE:STX's FCF Margin % is ranked worse than
93.47% of 1026 companies
in the Drug Manufacturers industry
Industry Median: -0.675 vs LSE:STX: -401.31

Shield Therapeutics FCF Margin % Historical Data

The historical data trend for Shield Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics FCF Margin % Chart

Shield Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

FCF Margin %

Get a 7-Day Free Trial

-26.88

-758.00

-13.70

-1,338.12

-429.98

Shield Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
FCF Margin %	Get a 7-Day Free Trial													-1,684.62	-1,177.55	-608.95	-177.50	-497.00

Competitive Comparison of Shield Therapeutics's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shield Therapeutics's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Shield Therapeutics's FCF Margin % falls into.

Shield Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Shield Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-19.207	/	4.467
	=	-429.98 %

Shield Therapeutics's FCF Margin for the quarter that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-21.54	/	4.334
	=	-497.00 %

Shield Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Shield Therapeutics (LSE:STX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

SHIEF:USA 1JS:Germany

Address

Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF

Website

https://www.shieldtherapeutics.com

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.